Free Trial
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

$16.59
+0.43 (+2.66%)
(As of 07/15/2024 ET)
Today's Range
$16.05
$16.89
50-Day Range
$12.19
$18.09
52-Week Range
$8.20
$18.75
Volume
319,006 shs
Average Volume
358,486 shs
Market Capitalization
$599.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.9% Upside
$32.00 Price Target
Short Interest
Bearish
9.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of iTeos Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.57) to ($5.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.25 out of 5 stars

Medical Sector

759th out of 913 stocks

Biological Products, Except Diagnostic Industry

136th out of 153 stocks

ITOS stock logo

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

ITOS Stock News Headlines

iTeos Therapeutics (NASDAQ:ITOS) Trading Up 3%
[Urgent] Protect your money before November
Do you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.
[Urgent] Protect your money before November
Do you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.
Iteos Therapeutics Inc (ITOS)
ITOS Oct 2024 17.000 call
ITOS Oct 2024 12.000 call
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2024
Today
7/15/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$46.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+93.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,640,000.00
Pretax Margin
-865.66%

Debt

Sales & Book Value

Annual Sales
$12.60 million
Book Value
$16.08 per share

Miscellaneous

Free Float
31,608,000
Market Cap
$598.92 million
Optionable
Optionable
Beta
1.40
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Michel Detheux Ph.D. (Age 57)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Matthew GallMr. Matthew Gall (Age 47)
    Chief Financial Officer
    Comp: $648k
  • Mr. Matthew A. Call M.B.A. (Age 51)
    Chief Operating Officer
    Comp: $706.21k
  • Dr. Yvonne McGrath Ph.D. (Age 50)
    Chief Scientific Officer
  • Ms. Adi Osovsky
    Executive Vice President of Legal
  • Mr. Philippe Brantegem
    Executive Vice President of Human Resources
  • Dr. Joyson Joseph Karakunnel FACP (Age 53)
    M.D., M.Sc., Interim Chief Medical Officer

ITOS Stock Analysis - Frequently Asked Questions

How have ITOS shares performed this year?

iTeos Therapeutics' stock was trading at $10.95 on January 1st, 2024. Since then, ITOS stock has increased by 51.5% and is now trading at $16.59.
View the best growth stocks for 2024 here
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its earnings results on Friday, May, 10th. The company reported ($1.07) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by $0.05.

When did iTeos Therapeutics IPO?

iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG) and Centene (CNC).

This page (NASDAQ:ITOS) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners